These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31005161)

  • 21. Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.
    Setyawan NH; Choridah L; Nugroho HA; Malueka RG; Dwianingsih EK
    Cancer Imaging; 2024 Jan; 24(1):3. PubMed ID: 38167551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
    Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
    Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
    Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
    Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.
    Throckmorton P; Graber JJ
    Neurology; 2020 Sep; 95(11):e1582-e1589. PubMed ID: 32690782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study.
    Park YW; Park KS; Park JE; Ahn SS; Park I; Kim HS; Chang JH; Lee SK; Kim SH
    Korean J Radiol; 2023 Feb; 24(2):133-144. PubMed ID: 36725354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
    Varughese RK; Skjulsvik AJ; Torp SH
    Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Histopathologic and Radiologic Features of T2-FLAIR Mismatch Sign in IDH-Mutant 1p/19q Non-codeleted Astrocytomas.
    Fujita Y; Nagashima H; Tanaka K; Hashiguchi M; Hirose T; Itoh T; Sasayama T
    World Neurosurg; 2021 May; 149():e253-e260. PubMed ID: 33610870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas.
    Tan Y; Zhang H; Wang X; Qin J; Wang L; Yang G; Yan H
    Clin Radiol; 2019 Apr; 74(4):314-320. PubMed ID: 30771996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
    Liu Z; Zhang T; Jiang H; Xu W; Zhang J
    Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
    Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
    Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
    Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
    Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
    Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
    Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.
    Osada Y; Saito R; Miyata S; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2021 Jul; 38(3):218-227. PubMed ID: 34269949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
    Doig D; Kachramanoglou C; Dumba M; Tona F; Gontsarova A; Limbäck C; Jan W
    Clin Radiol; 2021 Oct; 76(10):785.e9-785.e16. PubMed ID: 34289936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
    J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas.
    Lin AL; Rosenblum M; Mellinghoff IK; Tabar VS; Ogilvie S; Schaff L; Yang TJ; Young RJ; Taylor BS; Jonsson P; Bale TA
    Brain Pathol; 2020 May; 30(3):653-660. PubMed ID: 31984581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.
    Richardson TE; Sathe AA; Kanchwala M; Jia G; Habib AA; Xiao G; Snuderl M; Xing C; Hatanpaa KJ
    J Neuropathol Exp Neurol; 2018 Jul; 77(7):542-548. PubMed ID: 29741737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
    Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
    Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.